Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 15Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Ureteral Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × avelumab × 1 year × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡